SecBot SecBot
6-K ·Filed Jul 22, 2026

RDY

DR REDDYS LABORATORIES LTD
BEARISH
Impact 6/10
Horizonimmediate Processed3mo ago SEC0001575872-26-000522
Actionable Insight ▼ Bearish

The US generics business is under severe structural pricing pressure, with no near-term catalyst for reversal. Watch for further erosion in upcoming quarters and the pace of new product launches (79 ANDAs pending, 24 first-to-file). The semaglutide quality issue may signal broader manufacturing risk; monitor FDA inspection outcomes at the Biologics Hyderabad facility (7 observations in June 2026). Non-US growth is strong but insufficient to offset US headwinds. The new auditor appointment (Deloitte) is a governance change worth noting but not immediately material.

DirectionBearish
Confidencehigh
Horizonimmediate

Drug in focus

RDY drug pipeline →

semaglutide

◆ Mixed Named in this 6-K
Impact
Phase
Approved - Generic
Time to market
Already launched in India (March 2026) and Canada (May 2026), but supply halted until ~October 2026 due to API impurity. US market entry not expected until patent exclusivity ends ~2031-2032.
Next catalyst
None dated

What to watchWatch for Dr. Reddy's API remediation progress and the late-October 2026 supply restart timeline. The supply halt halved the FY27 production target from 12M to 6-7M pens and erased ~$678M in market cap. Any update on resolving the impurity issue, regulatory findings, or competitive dynamics (Apotex, USV) could move shares. US market entry (2031-2032 patent expiry) is the long-term prize but too distant to trade on now.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$11.38
T+0 close · Jul 22, 2026 · via day close
Latest settled
+13.36%
T+60 · $12.90
Vs SPY
+10.09%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 22 $11.38entry
  2. T+1 · 4mo ago +3.69%α +4.93% · $11.80
  3. T+5 · 4mo ago +3.34%α +5.74% · $11.76
  4. T+20 · 3mo ago +6.41%α +3.52% · $12.11
  5. T+60 · 5w ago +13.36%α +10.09% · $12.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's Q1 FY2027 results were sharply below prior year: revenue fell 6% YoY to Rs.80,705M, operating profit collapsed 78% to Rs.3,784M, and EPS dropped 69% to Rs.5.32. The US generics business was the primary drag, with North America revenue down 35% (41% in USD) due to price erosion and volume declines. Gross margin contracted 10.4pp to 46.5%, further pressured by a Rs.2,397M semaglutide inventory write-down. Growth in India (+17%), Emerging Markets (+31%), and Russia (+28%) partially offset the US decline but could not prevent a 69% profit plunge.

Key Facts

  • Revenue decreased 6% YoY to Rs.80,705M (Q1 FY2026: Rs.85,452M)
  • North America (US+Canada) revenue fell 35% to Rs.22,048M; in USD terms down 41%
  • Gross profit margin collapsed from 56.9% to 46.5%
  • Operating profit (results from operating activities) down 78% to Rs.3,784M
  • Net profit attributable to parent down 69% to Rs.4,435M; basic EPS Rs.5.32 vs Rs.17.04
  • Rs.2,397M provision for semaglutide inventory write-down due to API quality issue
  • SG&A expenses rose 12% YoY to Rs.28,820M (35.7% of revenue vs 30.0%)
  • India revenue +17%, Emerging Markets +31%, Russia +28% (INR terms)
  • Board appointed Deloitte Haskins & Sells as new independent auditor
  • Proposed dividend of Rs.8 per share (subject to shareholder approval)

Financial Impact

Revenue decline of ~Rs.4,747M ($50M) and net profit decline of ~Rs.9,743M ($103M) YoY; gross margin compression of 10.4pp represents ~Rs.11,087M in lost gross profit

revenuegross marginoperating profitnet incomeEPSUS segment revenue

Risk Factors

  • Continued US generic price erosion and volume declines
  • FDA regulatory actions or warning letters following June 2026 inspection
  • Additional costs or liabilities from semaglutide quality issue
  • Geopolitical risks in Russia/Ukraine (28% of revenue from Russia)
  • Ranitidine litigation settlement costs (Illinois cases pending)

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 10 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (RDY), Batch item 10001575872-26-000522
Exhibit: ex991_1.htm0001575872-26-000522
Document: 0001575872-26-000522-index-headers.html0001575872-26-000522
Document: 0001575872-26-000522-index.html0001575872-26-000522
Document: 0001575872-26-000522.txt0001575872-26-000522
6-K Filing (RDY), Batch item 60001575872-26-000522
Exhibit: ex991_1.htm0001575872-26-000522
Document: 0001575872-26-000522-index-headers.html0001575872-26-000522
Document: 0001575872-26-000522-index.html0001575872-26-000522
Document: 0001575872-26-000522.txt0001575872-26-000522

Track record

73 reports on RDY

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 22, 2026